Pamisel "Continuous Supply of Diagnostic Kit Materials Due to COVID-19 Impact"

[Asia Economy Reporter Hyunseok Yoo] Pharmicell announced on the 6th that after receiving an order worth approximately 1.57 million USD (about 1.9 billion KRW) from ThermoFisher Scientific in the United States on the 19th of last month, it has additionally secured an order for nucleosides worth about 1.14 million USD (approximately 1.4 billion KRW).

A company official stated, "Nucleosides are units that make up nucleic acids and are used as the main raw materials for various virus diagnostic kits, infectious disease diagnostic reagents, and new gene therapy drugs," adding, "The recent increase in nucleoside orders appears to be due to the rise in demand for virus diagnostic kits amid the spread of the novel coronavirus infection (COVID-19), leading to increased orders for our company, which has secured stable production capacity."

In particular, the official said, "With this order, as of early March, Pharmicell has already secured sales of 5.5 billion KRW, which is more than 78% of last year's total nucleoside sales of 7.1 billion KRW," and added, "Since ThermoFisher has requested to secure additional maximum quantities, nucleoside sales are expected to grow significantly this year."

Meanwhile, ThermoFisher processes the nucleosides provided by Pharmicell and supplies them to pharmaceutical companies and research institutes worldwide. Pharmicell's nucleosides have been recognized for their technology and production capacity and are supplied to major companies in the United States and Europe, currently occupying more than 80% of the global market for 'diagnostic and pharmaceutical nucleosides.'

This content was produced with the assistance of AI translation services.